Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
OBJECTIVES: To investigate the clinical value of human glandular kallikrein 2 (hK2) compared with free (f) and total (t) prostate-specific antigen (PSA) in the early detection of prostate cancer (PCa). METHODS: In PCa screening conducted in 1995 to 1996 in Göteborg, Sweden, 5853 of 9811 randomly sel...
Main Authors: | , , , , |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2000
|
_version_ | 1797104420221091840 |
---|---|
author | Becker, C Piironen, T Pettersson, K Hugosson, J Lilja, H |
author_facet | Becker, C Piironen, T Pettersson, K Hugosson, J Lilja, H |
author_sort | Becker, C |
collection | OXFORD |
description | OBJECTIVES: To investigate the clinical value of human glandular kallikrein 2 (hK2) compared with free (f) and total (t) prostate-specific antigen (PSA) in the early detection of prostate cancer (PCa). METHODS: In PCa screening conducted in 1995 to 1996 in Göteborg, Sweden, 5853 of 9811 randomly selected men (aged 50 to 66 years; median 61) accepted PSA testing; those with tPSA levels of 3. 0 ng/mL or greater were offered digital rectal examination, transrectal ultrasound, and sextant biopsies. Serum from 604 of 611 biopsied men (18% with positive digital rectal examinations, tPSA range 3.0 to 220 ng/mL, 144 men with PCa) was analyzed for hK2 (research assay) and tPSA and fPSA (Prostatus). Sera were stored at -20 degrees C for a maximum of 2 weeks for tPSA and fPSA and 3 years for hK2. RESULTS: hK2 levels and hK2 x tPSA/fPSA values were significantly elevated in men with PCa. Receiver operating characteristic data revealed that the area under the curve for hK2 x tPSA/fPSA was significantly greater than that for tPSA and greater, but not significantly greater, than that for percent fPSA. Also, the cancer-detecting sensitivity was significantly improved (P <0.05) using hK2 x tPSA/fPSA compared with tPSA and percent fPSA at specificity levels of 75% to 90%. At 75% specificity, a sensitivity of 74% was obtained compared with 64% or 54% using percent fPSA or tPSA; at 90% specificity, the corresponding sensitivity level was 55%, 41%, and 36%, respectively. CONCLUSIONS: Discrimination of men with and without PCa in a randomly selected population was improved by measuring hK2 in addition to tPSA and fPSA. |
first_indexed | 2024-03-07T06:33:32Z |
format | Journal article |
id | oxford-uuid:f6d5c26e-39f1-4d76-9925-b0bdc3bbe05d |
institution | University of Oxford |
language | English |
last_indexed | 2024-03-07T06:33:32Z |
publishDate | 2000 |
record_format | dspace |
spelling | oxford-uuid:f6d5c26e-39f1-4d76-9925-b0bdc3bbe05d2022-03-27T12:37:57ZClinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f6d5c26e-39f1-4d76-9925-b0bdc3bbe05dEnglishSymplectic Elements at Oxford2000Becker, CPiironen, TPettersson, KHugosson, JLilja, HOBJECTIVES: To investigate the clinical value of human glandular kallikrein 2 (hK2) compared with free (f) and total (t) prostate-specific antigen (PSA) in the early detection of prostate cancer (PCa). METHODS: In PCa screening conducted in 1995 to 1996 in Göteborg, Sweden, 5853 of 9811 randomly selected men (aged 50 to 66 years; median 61) accepted PSA testing; those with tPSA levels of 3. 0 ng/mL or greater were offered digital rectal examination, transrectal ultrasound, and sextant biopsies. Serum from 604 of 611 biopsied men (18% with positive digital rectal examinations, tPSA range 3.0 to 220 ng/mL, 144 men with PCa) was analyzed for hK2 (research assay) and tPSA and fPSA (Prostatus). Sera were stored at -20 degrees C for a maximum of 2 weeks for tPSA and fPSA and 3 years for hK2. RESULTS: hK2 levels and hK2 x tPSA/fPSA values were significantly elevated in men with PCa. Receiver operating characteristic data revealed that the area under the curve for hK2 x tPSA/fPSA was significantly greater than that for tPSA and greater, but not significantly greater, than that for percent fPSA. Also, the cancer-detecting sensitivity was significantly improved (P <0.05) using hK2 x tPSA/fPSA compared with tPSA and percent fPSA at specificity levels of 75% to 90%. At 75% specificity, a sensitivity of 74% was obtained compared with 64% or 54% using percent fPSA or tPSA; at 90% specificity, the corresponding sensitivity level was 55%, 41%, and 36%, respectively. CONCLUSIONS: Discrimination of men with and without PCa in a randomly selected population was improved by measuring hK2 in addition to tPSA and fPSA. |
spellingShingle | Becker, C Piironen, T Pettersson, K Hugosson, J Lilja, H Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. |
title | Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. |
title_full | Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. |
title_fullStr | Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. |
title_full_unstemmed | Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. |
title_short | Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. |
title_sort | clinical value of human glandular kallikrein 2 and free and total prostate specific antigen in serum from a population of men with prostate specific antigen levels 3 0 ng ml or greater |
work_keys_str_mv | AT beckerc clinicalvalueofhumanglandularkallikrein2andfreeandtotalprostatespecificantigeninserumfromapopulationofmenwithprostatespecificantigenlevels30ngmlorgreater AT piironent clinicalvalueofhumanglandularkallikrein2andfreeandtotalprostatespecificantigeninserumfromapopulationofmenwithprostatespecificantigenlevels30ngmlorgreater AT petterssonk clinicalvalueofhumanglandularkallikrein2andfreeandtotalprostatespecificantigeninserumfromapopulationofmenwithprostatespecificantigenlevels30ngmlorgreater AT hugossonj clinicalvalueofhumanglandularkallikrein2andfreeandtotalprostatespecificantigeninserumfromapopulationofmenwithprostatespecificantigenlevels30ngmlorgreater AT liljah clinicalvalueofhumanglandularkallikrein2andfreeandtotalprostatespecificantigeninserumfromapopulationofmenwithprostatespecificantigenlevels30ngmlorgreater |